Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$2.06
EPS est.
$1.96
EPS surprise
+5.21%
1-day move
-0.03%
Charles River Laboratories reported better-than-expected earnings per share, which indicates strong performance in that area. However, the stock reacted slightly down by 0.03%, suggesting that investors may have been looking for more clarity on revenue or future guidance, which was not provided.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.06 | $1.94 | +5.21% |
| Revenue | — | $977M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Charles River Laboratories International, Inc. (CRL) operates in the health care sector, specifically in life sciences tools and services. The company plays a crucial role in supporting the pharmaceutical and biotechnology industries by providing essential services for drug development and testing, which are vital for bringing new therapies to market.
Last quarter
In the last quarter, Charles River reported an EPS of $2.39, beating estimates by 2.49%. However, the stock experienced a slight decline the following day, indicating mixed market reactions.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+9.57%
Avg 1-day reaction
+4.27%
Analysts expect CRL to report solid earnings this quarter, with a consensus EPS of $1.94. The market is watching closely for any signs of growth in revenue and profitability.
Bull case
If CRL exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its services, leading to a positive market reaction.
Bear case
Conversely, if the company fails to meet earnings expectations or shows signs of declining revenue, it could raise concerns about its growth prospects, resulting in a negative market response.
Key metrics to watch
EPS
$1.94Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profit.
Revenue
$977MTotal revenue gives insight into the company's sales performance and demand for its services, which is critical for growth.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.94?
A beat on EPS could reinforce investor confidence in the company's profitability and growth trajectory.
Q2
What revenue guidance will management provide for the upcoming quarters?
Revenue guidance is crucial for assessing future growth potential and could significantly impact investor sentiment.
—
Est. EPS
$-0.76
Est. Rev
$192M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may underestimate CRL's ability to capitalize on increasing demand for drug development services, given its strong track record.
Supporting evidence
CRL has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in the biotech sector show increased investment in R&D, which could benefit CRL.
Key risk
If revenue growth significantly exceeds expectations, it could shift market sentiment positively.
Pre-commit to what would confirm each case.
The market is debating whether CRL can maintain its growth trajectory amid competitive pressures and economic conditions.
Bull confirmed if
Earnings exceeding $1.94 with revenue growth above $977M would confirm a bullish outlook.
Bear confirmed if
Failing to meet the $1.94 EPS and showing stagnant or declining revenue would validate bearish concerns.
What the market is pricing for the move.
Implied Move
±11.28%
Historical Avg
±8.3%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±11.3% while CRL has averaged ±8.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
52.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.3% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$2,974.30
10 sh
1 insider
Sold
$302,579.64
981 sh
1 insider
Net
$299,605.34
Net selling
Most Active Insiders· 2 open-market trades
$302,579.64
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
122.92%
of float
Insider
0.47%
of float
Holders
801
institutions
Top Holders· as of Jun 2026
FMR, LLC
4,239,752 sh · $1.3B
8.88%
22.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CRL beats expectations, history suggests the stock could rise by around 1.0%, confirming a positive outlook.
In line / cautious
An in-line report may lead to a muted response, as investors assess management's commentary for future guidance.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 0.0% when missing expectations.
The lines on the call that would change the story.
$2,974.30
Net buying
Recent Transactions
Oct 5, 2026 · @ $308.44
981 sh
$302,579.64
Sep 30, 2026 · @ $297.43
10 sh
$2,974.30
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
3,798,560 sh · $1.1B
7.96%
-1.6%
Vanguard Capital Management LLC
3,149,288 sh · $945.7M
6.60%
-1.7%
Invesco Ltd.
2,984,785 sh · $896.3M
6.25%
24.5%
Harris Associates L.P.
2,241,144 sh · $673.0M
4.69%
4.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.